Resources Repository
-
Resource PortalWeb Portal, Teaching Resource 2024National Academies of Sciences, Engineering, and Medicine
The National Academies of Sciences, Engineering, and Medicine, founded in 1863, has a mission to provide …
The National Academies of Sciences, Engineering, and Medicine, founded in 1863, has a mission to provide nonpartisan, objective guidance for decision makers on policy challenges in the context of science, engineering, and medicine. NAS reports and convening activities have a wide range of impacts on policy and practice. They guide the development of federal laws and regulations, improve the effectiveness of government programs, shape the direction of research fields, and inform public knowledge and dialogue about…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Outcomes | Evidence Synthesis | Risk Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Global Governance | Climate/Environment | Energy/Engineering | Education/Labor | Food/Agriculture | Health/Medicine | Military/Defense | Science/Technology | Global | North America | High School | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ReviewPublication 2016Cost-Effectiveness Studies Reporting Cost-per-DALY Averted
This is a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015 …
This is a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015 conducted using the Global Health Cost-Effectiveness Analysis (GHCEA) Registry. Authors summarized descriptive characteristics on study methodology. They analyzed a) the types of costs included, b) study quality and c) the correlation between diseases researched and the burden of disease in different world regions. 479 cost-per-DALY averted studies were published from 2000 through 2015, with studies from Sub-Saharan Africa representing the largest portion…
Cost-Effectiveness Analysis | Health Outcomes | Health Systems | Health/Medicine | Global -
ArticlePublication 2016Funding Gap for Immunization Across 94 Low- and Middle-Income Countries
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 …
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 low- and middle-income countries over the five-year period of 2016–2020. Vaccine financing by country governments, GAVI, and other development sources was forecasted for vaccine, supply chain, and service delivery based on an analysis of comprehensive multi-year plans together with a series of scenarios. The authors found that that delivery of full vaccination programs across the 94 countries would result in a total…
Cost-Effectiveness Analysis | Costing Methods | Mathematical Models | Infectious Diseases | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Reproductive, Maternal, Newborn, and Child Health: Key Messages from DCP3
As part of the Disease Control Priorities, Third Edition, the World Bank has published a …
As part of the Disease Control Priorities, Third Edition, the World Bank has published a volume on Reproductive, Maternal, Newborn and Child Health that identifies essential cost-effective health interventions that can be scaled-up now to reduce maternal, newborn and child deaths, and stillbirths. This article summarizes the key findings and estimates the impact and cost of expanded implementation of these interventions. Scaling up all preventive and therapeutic health interventions in these integrated packages from current…
Cost-Effectiveness Analysis | Costing Methods | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Health/Medicine | Global -
ArticlePublication 2016Health, Financial and Distributional Consequences of Tobacco Excise Tax in Lebanon
This paper considers the financial and health effects, by socio-economic class, of increasing tobacco taxes …
This paper considers the financial and health effects, by socio-economic class, of increasing tobacco taxes in Lebanon, a middle-income country. Extended cost-effectiveness analysis (ECEA) methods are applied to quantify, across quintiles of socio-economic status, the health benefits gained, the additional tax revenues raised, and the net financial consequences for households from a 50% increase in the price of tobacco through excise taxes. The increase in tobacco tax is estimated to result in 65,000 premature deaths…
Cost-Effectiveness Analysis | Costing Methods | Chronic Disease/Risk | Policy/Regulation | Health/Medicine | Middle East & North Africa -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Europe | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Mathematical Models | Dynamic Transmission | Infectious Diseases | Child/Nutrition | Health Systems | Global Governance | Climate/Environment | Economics/Finance | Health/Medicine | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness Thresholds: Pros and Cons
This WHO bulletin compares the two main methods for comparing the cost-effectiveness of health interventions. …
This WHO bulletin compares the two main methods for comparing the cost-effectiveness of health interventions. Cost-effectiveness thresholds allow health decision makers to identify cost-effectiveness ratios that represent good or bad value for money. In 2001, the World Health Organization's Commission on Macroeconomics in Health suggested cost-effectiveness thresholds based on multiples of a country's per-capita gross domestic product (GDP). In some contexts, these thresholds have been used as decision rules. However, this approach lacks country specificity…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Health/Medicine -
ArticlePublication 2016Cost-Effectiveness of Hypertension Treatment According to 2014 Guidelines
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according …
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according to 2014 US hypertension treatment guidelines. The cardiovascular disease (CVD) policy model was used to simulate CVD events, quality-adjusted life years (QALYs), and treatment costs in 35- to 74-year-old adults with untreated hypertension. CVD incidence, mortality, and risk factor levels were obtained from cohort studies, hospital registries, vital statistics, and national surveys. The authors assumed a willingness-to-pay for health of…
Cost-Effectiveness Analysis | Microsimulation | Chronic Disease/Risk | Health/Medicine | North America